7 – 9 February 2018 Madrid
![]() |
![]() |
![]() |
![]() |
4-P | PREVALENCE OF VITAMIN D DEFICIENCY IN PERSONS WITH SEVERE HAEMOPHILIA IN IRELAND | Deirdre Gorman | ![]() |
![]() |
|||
5-P | CHRONIC PAIN IN HAEMOPHILIA:EVIDENCE BASED PSYCHOLOGICAL APPROACHES TO BETTER MANAGEMENT | Cleary Janet | ![]() |
![]() |
|||
6-P | PERSISTENT EFFECTIVENESS OF PROPHYLAXIS WITH RECOMBINANT FACTOR VIII CONCENTRATE IN PATIENTS WITH HEMOPHILIA A IN A REAL WORLD SETTING OVER 4 YEARS (INTERNATIONAL AHEAD STUDY) | Dana Scott | ![]() |
![]() |
|||
14-P | OUTPATIENT PHYSIOTERAPIC MANAGEMENT AT BIANCHI BONOMI HEMOFILIA CENTER: 20-YEAR EXPERIENCE | Boccalandro Elena | ![]() |
![]() |
|||
21-P | SAFETY AND EFFECTIVENESS OF FASCIAL THERAPY IN ADULT PATIENTS WITH HEMOPHILIC ARTHROPATHY OF ANKLE. A COHORT STUDY. | Rubén Cuesta-Barriuso | ![]() |
![]() |
|||
22-P | SAFETY AND EFFICACY OF MANUAL AND EDUCATIONAL THERAPY IN THE TREATMENT OF HEMOPHILIC ARTHROPATHY OF THE ELBOW. A RANDOMIZED CLINICAL TRIAL. | Rubén Cuesta-Barriuso | ![]() |
![]() |
|||
30-P | HEALTH RELATED QUALITY OF LIFE, DEVELOPMENTAL MILESTONES AND SELF-ESTEEM IN YOUNG ADULTS WITH CONGENITAL BLEEDING DISORDERS | Lotte Haverman | ![]() |
![]() |
|||
41-P | BLEEDING RISK IN HEMOPHILIA PATIENT UNDERGOING ANTITHROMBOTIC THERAPY, RESULTS OF THE EHREA MULTICENTRIC STUDY | ALEXANDRE DESJONQUERES | ![]() |
![]() |
|||
43-P | COMPARISON OF THREE ASSAYS FOR MEASURING FACTOR IX | Amy DERICQUEBOURG | ![]() |
![]() |
|||
49-P | CLINICAL REVIEW OF PIVOTAL TRIALS ON OCTOCOG-ALFA (KOVALTRY) AND OTHER RECOMBINANT FVIII IN PATIENTS WITH HAEMOPHILIA A | Lucia Sara DAngiolella | ![]() |
![]() |
|||
51-P | BENEFITS OF SWITCH TO FVIII-FC: EXPERIENCE OF PROPHYLAXIS IN EIGHT PATIENTS | annarita tagliaferri | ![]() |
![]() |
|||
53-P | THE FIX:C ASSESSMENT OF EXTENDED HALF-LIFE RECOMBINANT FACTOR IX PRODUCTS IN CLINICAL PRACTICE | Annette Bowyer | ![]() |
![]() |
|||
55-P | Comparison of Standard Half-Life to Extended Half-Life FIX Products: Real-World Analysis of Recent Factor IUs Dispensed and Expenditures in On-Demand Hemophilia B Patients | Ashley Daset | ![]() |
![]() |
|||
60-P | IMPACT OF PRE-EXISTING IMMUNITY TO AAV5 ON PHARMACODYNAMICS OF BMN 270, AN AAV5-BASED GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA A | Simin Batroff | ![]() |
![]() |
|||
61-P | INTERIM ANALYSIS OF IMMUNOGENICITY TO THE VECTOR CAPSID AND TRANSGENE-EXPRESSED HUMAN FVIII IN A PHASE-1/2 CLINICAL STUDY OF BMN-270, AN AAV5 MEDIATED GENE THERAPY FOR HEMOPHILIA A | Simin Batroff | ![]() |
![]() |
|||
68-P | PATIENTS WITH BLEEDING OF UNKNOWN CAUSE AND JOINT HYPERMOBILITY: CLINICAL ASSESSMENT AND GENETIC SCREENING | marta Martorell | ![]() |
![]() |
|||
71-P | PREVALENCE OF OVERWEIGHT IN YOUNG PATIENTS WITH SEVERE HAEMOPHILIA AND ITS ECONOMIC BURDEN IN GERMANY | Christoph Bidlingmaier | ![]() |
![]() |
|||
75-P | THE WFH WORLD BLEEDING DISORDERS REGISTRY | Mark Brooker | ![]() |
![]() |
|||
83-P | PATIENT PERSPECTIVES ON CURRENT AND FUTURE HAEMOPHILIA TREATMENT | Erna van Balen | ![]() |
![]() |
|||
85-P | DRUG CONSUMPTION AND COST ESTIMATES FOR DIFFERENT RECOMBINANT FACTOR VIII PRODUCTS APPROVED FOR REPLACEMENT TREATMENT IN PATIENTS WITH HEMOPHILIA A IN ITALY | Alessandro ROGGERI | ![]() |
![]() |
|||
97-P | PERIPROSTHETIC BONE MINERAL DENSITY AFTER ANKLE PROTHESIS. PRELIMINARY OBSERVATIONS FROM TWO CLINICAL CASES. | Giulia Rebagliati | ![]() |
![]() |
|||
114-P | ASSOCIATED IMPACT OF ACTIVITY IMPAIRMENT ON CLINICAL AND PATIENT-CENTRIC OUTCOMES IN SEVERE HAEMOPHILIA | Aji NAIR | ![]() |
![]() |
|||
115-P | ASSOCIATED IMPACT OF WORK IMPAIRMENT ON CLINICAL AND PATIENT-CENTRIC OUTCOMES IN SEVERE HAEMOPHILIA | Aji NAIR | ![]() |
![]() |
|||
117-P | RECOMBINANT VON WILLEBRAND FACTOR (RVWF) ADMINISTRATION: DOSING CONSIDERATIONS AND RAPID STABILIZATION OF ENDOGENOUS PLASMA FVIII LEVELS IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE | Dana Scott | ![]() |
![]() |
|||
118-P | DOES ADAMTS13 INFLUENCE THE BLEEDING PHENOTYPE IN PATIENTS WITH VON WILLEBRAND DISEASE? | Johan Boender | ![]() |
![]() |
|||
121-P | SIMULTANEOUS THROMBIN AND PLASMIN GENERATION IN PATIENTS WITH PLASMINOGEN OR PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 DEFICIENCY | Joline Saes | ![]() |
![]() |
|||
122-P | WHOLE EXOME SEQUENCING IN PATIENTS WITH A BLEEDING TENDENCY | Joline Saes | ![]() |
![]() |
|||
125-P | ONLINE COURSE OF PHARMACOKINETIC MONITORING IN HEMOPHILIA WITH APPLICATION IN THE CLINICAL PRACTICE | Juan Eduardo Megías Vericat | ![]() |
![]() |
|||
126-P | INDIVIDUALIZATION OF PROPHYLAXIS WITH RECOMBINANT FACTOR VIII IN SEVERE OR MODERATE HEMOPHILIA A | Juan Eduardo Megías Vericat | ![]() |
![]() |
|||
128-P | PHYSICAL ACTIVITY AND HEALTH OUTCOMES IN SEVERE HEMOPHILIA A PATIENTS ON PROPHYLAXIS WITH CONVENTIONAL RFVIII VS. RFVIIIFC | Nanxin Li | ![]() |
![]() |
|||
129-P | CASE REPORT: A SUCCESSFUL PREGNANCY IN HAEMOPHILLIA A | Jun Yong | ![]() |
![]() |
|||
145-P | INSIGHT INTO THE REAL-LIFE OF PERSONS WITH HAEMOPHILIA (PWH).IMPACT OF RECENTLY INTRODUCED PROPHYLACTIC REPLACEMENT | Margit Serban | ![]() |
![]() |
|||
150-P | DOES BLOOD GROUP 0 INFLUENCE INHIBITOR DEVELOPMENT? DATA FROM THE PEDNET REGISTRY | Marloes de Kovel | ![]() |
![]() |
|||
152-P | F9 GENOTYPE AND PK HEMOPHILIA B ITALIAN STUDY (GEPKHIS | Massimo Morfini | ![]() |
![]() |
|||
154-P | HEMOPHILIACS MANAGEMENT IN AN EMERGENCY DEPARTMENT:A 7-YEARS SURVEY TO IDENTIFY AREAS FOR SAFETY AND QUALITY IMPROVEMENT. | Michael HOANG | ![]() |
![]() |
|||
156-P | JOINT OUTCOME IN FOUR YEARS FOLLOW-UP IN CHILDREN WITH HEMOPHILIA TREATED WITH EARLY PROPHYLAXIS | Minna Koskenvuo | ![]() |
![]() |
|||
158-P | PLATELETS DISORDER IN A CASE OF CHRONIC LYMPHOCYTIC LEUKEMIA (LLC) | Corrado Lodigiani | ![]() |
![]() |
|||
163-P | AUDIT OF BLEEDING COMPLICATIONS FOLLOWING INVASIVE PROCEDURES AND MINOR SURGERIES IN PATIENTS WITH BLEEDING DISORDERS: CONSIDERING A RATIONALE FOR SAFE SAME DAY DISCHARGE | Naoimh Herlihy | ![]() |
![]() |
|||
165-P | EFFICACY ON PAIN OF A SINGLE INJECTION OF HYALURONIC ACID IN HAEMOPHILIC ARTHROPATHY OF THE ANKLE: A PROSPECTIVE STUDY | Castet Sabine | ![]() |
![]() |
|||
177-P | ANNUAL BLEEDING RATE AND BLEEDING-RELATED FACTOR-REPLACEMENTTHERAPYCOSTS IN HEMOPHILIA A AND B IN REAL-LIFE CLINICAL PRACTICE: A 4-YEAR FOLLOW-UP STUDY IN FINLAND | Riitta Lassila | ![]() |
![]() |
|||
179-P | REAL-WORLD BLEEDING FREQUENCY IN INHIBITOR PATIENTS ON PROPHYLAXIS WITH APCC: DATA READ-OUT OF THE FEIBA GLOBAL OUTCOMES STUDY (FEIBA GO) | Dana Scott | ![]() |
![]() |
|||
180-P | TOLERABILITY/SAFETY OF FEIBA RECONSTITUTED IN REGULAR OR 50 REDUCED VOLUME AND FASTER INFUSION RATES: RATIONALE AND STUDY DESIGN IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS | Dana Scott | ![]() |
![]() |
|||
181-P | REAL WORLD USE OF B-DOMAINDELETED, PORCINE-SEQUENCE FACTOR VIII (RPFVIII) IN PATIENTS WITH ACQUIRED HAEMOPHILIA A (AHA): POST-MARKETING SAFETY (PMS) STUDIES IN EUROPEAN UNION (EU) AND IN THE UNITED STATES (US) | Dana Scott | ![]() |
![]() |
|||
184-P | COMBINED PROTHROMBIN AND FACTOR XI DEFICIENCY IN A LEBANESE FAMILY | Roula Farah | ![]() |
![]() |
|||
186-P | MEASUREMENT OF JOINT STATUS IN PATIENTS WITH HAEMOPHILIA: A SYSTEMATIC REVIEW OF THE MEASUREMENT PROPERTIES OF HAEMOPHILIA-SPECIFIC JOINT EXAMINATION SCORES | Samantha Gouw | ![]() |
![]() |
|||
191-P | RECOMBINANT FVIII PRODUCT TYPE AND THE RISK OF INHIBITOR DEVELOPMENT IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA A: A SYSTEMATIC REVIEW AND META-ANALYSIS | Shermarke Hassan | ![]() |
![]() |
|||
196-P | THERAPEUTIC LEVELS OF HUMAN FVIII IN MICE AND PRIMATES AND NORMALIZATION OF BLEEDING IN HEMOPHILIC MICE FOLLOWING GENE THERAPY WITH BMN 270 | Sylvia Fong | ![]() |
![]() |
|||
197-P | MANAGMENT OF DELIVERIES IN CARRIERS FOR HEMOPHILA A AND LOW FVIII LEVELS WITH RECOMBINANT FVIIIFC FUSION PROTEIN | Susan Halimeh | ![]() |
![]() |
|||
202-P | SURGICAL INTERVENTIONS IN PATIENTS WITH HEMOPHILIA: OUTCOME OF TREATMENT AT A SINGLE CENTER IN LOW-RESOURCE SETTINGS | Tuan NGUYEN | ![]() |
![]() |
7 – 9 February 2018 Madrid
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|